2-acetylaminofluorene has been researched along with pioglitazone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Borbath, I; Horsmans, Y; Leclercq, I; Moulin, P; Sempoux, C | 1 |
2 other study(ies) available for 2-acetylaminofluorene and pioglitazone
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver.
Topics: 2-Acetylaminofluorene; Animals; Anticarcinogenic Agents; Apoptosis; Blotting, Western; Carcinogens; Carcinoma, Hepatocellular; Cell Proliferation; Chemoprevention; Diethylnitrosamine; Immunohistochemistry; Ki-67 Antigen; Liver Neoplasms; Male; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Thiazolidinediones | 2007 |